Literature DB >> 18805385

Interventional management of critical limb ischemia in renal patients.

Ivan P Casserly1.   

Abstract

Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral arterial disease (PAD), defined as the presence of chronic ischemic rest pain, ulcers, or gangrene attributable to objectively proven arterial occlusive disease. The occurrence of CLI in patients with kidney insufficiency portends a strikingly high rate of subsequent morbidity and mortality. Generally, the primary therapy for CLI is revascularization of the affected limb. However, patients with CLI and kidney insufficiency represent a unique and challenging patient subset, and data from surgical series suggest reduced rates of limb salvage and higher medium and long-term mortality rates for patients with kidney insufficiency compared with those with normal kidney function. In contemporary practice, endovascular techniques are fast replacing surgical bypass as the first-line revascularization strategy for CLI, based on high technical success rates and low rates of procedure-related morbidity and mortality. However, a large series on endovascular outcomes for the treatment of CLI in patients with kidney insufficiency is lacking. Based on the severely reduced long-term survival rates of patients with CLI and kidney insufficiency, future efforts should focus on early detection of PAD in patients with kidney insufficiency and institution of aggressive medical therapy to prevent progression in the global burden of atherosclerosis in this patient population.

Entities:  

Mesh:

Year:  2008        PMID: 18805385     DOI: 10.1053/j.ackd.2008.07.008

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  4 in total

1.  Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia.

Authors:  Motoyuki Kumagai; Akira Marui; Yasuhiko Tabata; Takahide Takeda; Masaya Yamamoto; Atsushi Yonezawa; Shiro Tanaka; Shigeki Yanagi; Toshiko Ito-Ihara; Takafumi Ikeda; Toshinori Murayama; Satoshi Teramukai; Toshiya Katsura; Kazuo Matsubara; Koji Kawakami; Masayuki Yokode; Akira Shimizu; Ryuzo Sakata
Journal:  Heart Vessels       Date:  2015-04-11       Impact factor: 2.037

Review 2.  Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes.

Authors:  Pranav S Garimella; Alan T Hirsch
Journal:  Adv Chronic Kidney Dis       Date:  2014-10-24       Impact factor: 3.620

3.  The open retrograde approach as an alternative for failed percutaneous access for difficult below the knee chronic total occlusions-A case series.

Authors:  K Saravana; Y K Tan; S Kum; T Y Tang
Journal:  Int J Surg Case Rep       Date:  2015-09-24

Review 4.  Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease.

Authors:  Szu-Chun Hung; Ko-Lin Kuo; Chih-Cheng Wu; Der-Cherng Tarng
Journal:  J Am Heart Assoc       Date:  2017-02-07       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.